Although venetoclax is a selective small-molecule Bcl-2 inhibitor, it is ineffective against cancer cells with high Mcl-1 levels, including MM (Phillips et al., 2015; Bodo et al., 2016; Konopleva et al., 2016; Punnoose et al., 2016b). This evidence concerns the gene BCL2 and cancer.